Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $12.72 million. The enterprise value is $9.94 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 4.24 million shares outstanding. The number of shares has increased by 41.83% in one year.
| Current Share Class | 4.24M |
| Shares Outstanding | 4.24M |
| Shares Change (YoY) | +41.83% |
| Shares Change (QoQ) | +10.34% |
| Owned by Insiders (%) | 17.65% |
| Owned by Institutions (%) | 30.54% |
| Float | 3.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.41 |
| Forward PS | n/a |
| PB Ratio | 1.89 |
| P/TBV Ratio | 1.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80
| Current Ratio | 1.80 |
| Quick Ratio | 1.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -67.77% and return on invested capital (ROIC) is -53.99%.
| Return on Equity (ROE) | -67.77% |
| Return on Assets (ROA) | -45.81% |
| Return on Invested Capital (ROIC) | -53.99% |
| Return on Capital Employed (ROCE) | -99.03% |
| Weighted Average Cost of Capital (WACC) | 14.00% |
| Revenue Per Employee | $1.99M |
| Profits Per Employee | -$5.28M |
| Employee Count | 1 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.03% in the last 52 weeks. The beta is 1.77, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | +2.03% |
| 50-Day Moving Average | 3.07 |
| 200-Day Moving Average | 2.11 |
| Relative Strength Index (RSI) | 47.49 |
| Average Volume (20 Days) | 49,795 |
Short Selling Information
The latest short interest is 26,663, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 26,663 |
| Short Previous Month | 56,618 |
| Short % of Shares Out | 0.63% |
| Short % of Float | 0.76% |
| Short Ratio (days to cover) | 0.22 |
Income Statement
In the last 12 months, CYCN had revenue of $1.99 million and -$5.28 million in losses. Loss per share was -$1.47.
| Revenue | 1.99M |
| Gross Profit | 340,000 |
| Operating Income | -6.73M |
| Pretax Income | -5.28M |
| Net Income | -5.28M |
| EBITDA | n/a |
| EBIT | -6.73M |
| Loss Per Share | -$1.47 |
Full Income StatementBalance Sheet
The company has $2.82 million in cash and n/a in debt, with a net cash position of $2.82 million or $0.67 per share.
| Cash & Cash Equivalents | 2.82M |
| Total Debt | n/a |
| Net Cash | 2.82M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 6.79M |
| Book Value Per Share | 1.60 |
| Working Capital | 1.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.52 million and capital expenditures -$66,000, giving a free cash flow of -$3.59 million.
| Operating Cash Flow | -3.52M |
| Capital Expenditures | -66,000 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -3.59M |
| FCF Per Share | -$0.85 |
Full Cash Flow StatementMargins
Gross margin is 17.06%, with operating and profit margins of -337.43% and -264.73%.
| Gross Margin | 17.06% |
| Operating Margin | -337.43% |
| Pretax Margin | -264.73% |
| Profit Margin | -264.73% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.83% |
| Shareholder Yield | -41.83% |
| Earnings Yield | -41.33% |
| FCF Yield | -28.11% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 467.81% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 16, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 16, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
CYCN has an Altman Z-Score of -44.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -44.75 |
| Piotroski F-Score | 2 |
